- Chief Medical Officer Dr. Sam Barone to join the Emerging Innovations in Retinal Therapies panel; Company to present an update on MOGENRY®in the Retina Drug Delivery New Targets Showcase at Eyecelerator 2026.
- Four-year REMAIN data from the RESTORE Phase 2b/3 trial of MCO-010 in retinitis pigmentosa and a scientific poster on dry AMD to be presented at the AAO 2026 Annual Meeting, October 8–13, 2026, in New Orleans, Louisiana.
DALLAS, Oct. 6, 2026 /PRNewswire/— Terapéutica del nanoscopio, Inc., a biotechnology company committed to developing and commercializing novel, disease-agnostic therapies for patients with photoreceptor loss and vision impairment due to retinal degeneration, today announced that its optogenetics gene therapy (MOGENRY, MCO-010) will be featured in various scientific programming at the American Academy of Ophthalmology (AAO) 2026 annual meeting taking place October 8–13, 2026, in New Orleans. Additionally, the company will participate in Eyecelerator@AAO 2026 with a company presentation and panel participation. Eyecelerator brings together ophthalmic innovators, industry leaders, clinicians, and investors to accelerate the development of new therapies and technologies in eye care. The AAO Annual Meeting is the world’s largest gathering of ophthalmologists and eye care professionals.
Eyecelerator Presentation Details:
Eyecelerator 2026, Ernest N. Morial Convention Center
Panel: Emerging Innovations in Retinal Therapies
Miembro del jurado: Sam Barone, MD, Chief Medical Officer
Fecha y hora: Thursday, October 8, 2026, 10:45–11:30 AM CT
Ubicación: La Nouvelle Ballroom C
Company Presentation: Retina Drug Delivery & New Targets Showcase
Presentador: Paul Hallen, Chief Operating Officer
Fecha y hora: Thursday, October 8, 2026, 1:00–1:05 PM CT
Ubicación: Rooms 252–254
AAO Presentation Details:
AAO 2026 Annual Meeting, Ernest N. Morial Convention Center
Presentación: Lasting vision Improvement in Retinitis Pigmentosa: REMAIN 4-Year Study Data From the RESTORE Phase 2b/3 Trial of MCO-010 Optogenetic Therapy
Sesión: PA044
Presentador: Kenneth C. Fan, MD
Fecha y hora: Sunday, October 11, 2026, 11:42–11:49 AM CT
Ubicación: Rooms 255–257
Scientific Poster: Vision Improvement in Dry AMD With Sonpiretigene Isteparvovec Optogenetic Therapy: First Direct-to-Phase 2 RCT
Sesión: PO624
Presentador: David S. Boyer, MD
Availability: On demand
During the panel, Dr. Barone will join fellow industry leaders to discuss emerging approaches in retinal therapeutics, including the potential of mutation-agnostic optogenetic gene therapy for patients with advanced retinal degeneration. In the Showcase presentation, Mr. Hallen will provide an update on Nanoscope’s progress toward potential global approval of its lead asset, MOGENRY® (sonpiretigene isteparvovec; MCO-010), for the treatment of inherited retinal dystrophies, including the status of the Company’s Biologics License Application (BLA), y Japan New Drug Application (JNDA), currently under FDA and PMDA review respectively. At AAO 2026, Dr. Fan will present four-year data from the REMAIN study of patients treated in the RESTORE Phase 2b/3 trial, highlighting the durability of vision improvement with MCO-010 in retinitis pigmentosa. Dr. David S. Boyer will also present a scientific poster, available on demand, on vision improvement with sonpiretigene isteparvovec in dry AMD from the first direct-to-Phase 2 randomized controlled trial. Members of the Nanoscope leadership team will be available to meet with retina specialists, investors, and potential partners throughout Eyecelerator and AAO 2026.
Nanoscope team members will be available at Booth 2564 for the duration of the AAO conference.
About MOGENRY (sonpiretigene isteparvovec; MCO-010)
Nanoscope’s multi-characteristic opsin (MCO) technology utilizes a proprietary genetically engineered synthetic opsin to enable optimized performance in terms of high light sensitivity across a broad spectrum and fast kinetics. After Nanoscope’s Co-Founder, President, and Chief Scientific Officer, Samarendra Mohanty, envisioned and invented the technology, his team has spent over a decade evaluating its performance across multiple animal models and human diseases. MOGENRY is an investigational, one-time, in-office, intravitreal optogenetic gene therapy built on Nanoscope’s MCO platform. By delivering a multi-characteristic opsin gene to the highly dense bipolar retinal cells, MOGENRY makes these surviving cells directly light-sensitive, enabling them to utilize the remaining visual circuitry following photoreceptor loss. MOGENRY does not require genetic testing, invasive surgery, or repeat dosing, and is designed for administration within existing retina office workflows. MOGENRY is under review by the FDA for the treatment of RP with severe vision loss and under priority review by the PMDA and MHLW for the treatment of IRDs in Japan. The 2026 Nobel Prize in Physiology or Medicine was recently awarded to the three scientists who pioneered optogenetics, the scientific foundation that Nanoscope’s development programs, including MOGENRY, are built upon.
Acerca de Nanoscope Therapeutics
Nanoscope Therapeutics está desarrollando una terapia optogenética restauradora de la visión, independiente de la enfermedad, para millones de pacientes ciegos por enfermedades degenerativas de la retina. Tras los resultados positivos del ensayo clínico multicéntrico, aleatorizado, doble ciego y controlado con placebo RESTORE Fase 2b/3 para la retinosis pigmentaria (NCT04945772), el FDA has accepted and filed the Company’s BLA for MOGENRY, and the PMDA has accepted for priority review the Company’s NDA for MOGENRY for the treatment of IRDs in Japan. If approved, MOGENRY has the potential to become the standard of care for patients with RP and other IRDs, administered as a one-time, in-office injection without the need for genetic testing. The Company has also shown promising results in the STARLIGHT Phase 2 clinical trial of MCO-010 in Stargardt disease (SD) (NCT05417126) y planea iniciar un ensayo de registro de Fase 3 en 2026. MCO-010 ha recibido las designaciones de Vía Rápida y Medicamento Huérfano de la FDA para RP y SD, junto con la designación RMAT para SD, y las designaciones de Medicamento Huérfano de la EMA que cubren distrofias dominantes de bastones y conos no sindrómicas y sindrómicas, así como distrofias maculares. MCO-010 también ha recibido las designaciones de Sakigake y Medicamento Huérfano para distrofias retinianas hereditarias (IRD) en Japón y una designación de Medicamento Huérfano para IRD en Arabia Saudita. Se espera que un programa de Fase 2 para MCO en atrofia geográfica comience en 2026, y otros programas listos para IND incluyen amaurosis congénita de Leber (LCA).
Learn more at NanosTherapeutics.com and follow @NSTherapeutics on X and on LinkedIn.
Contacto:
Nanoscope Therapeutics, Inc
(817) 857-1186
PR@nanostherapeutics.com
FUENTE Terapéutica del Nanoscopio